Horich William Todd has disclosed the acquisition of 100,000 restricted stock units (RSUs) in Supernus Pharmaceuticals, Inc. This transaction is significant as it aligns with the company’s strategic direction amidst a merger with Indivior Pharmaceuticals, Inc. The vesting of these RSUs is structured to occur over four years, reflecting a long-term commitment to the company’s growth and stability.

Background

Horich William Todd is an executive at Supernus Pharmaceuticals, Inc., a company classified under the pharmaceutical preparations sector. The company is based in Rockville, Maryland, and has been active in the pharmaceutical industry, focusing on developing and commercializing products for central nervous system disorders. Recent filings indicate ongoing activities related to corporate governance and executive compensation.

What the Filing Says

The recent filing, dated November 2, 2026, indicates that Todd acquired 100,000 RSUs, which will vest in installments tied to the merger with Indivior Pharmaceuticals. The filing states, “These restricted stock units are settled in common stock upon vesting, which occurs in four installments.” The first vesting occurs upon the closing of the merger, with subsequent vesting at one-year intervals thereafter.

Impact

This acquisition may affect Supernus Pharmaceuticals' operational strategies and employee retention efforts. By tying executive compensation to the merger’s success, the company aims to align the interests of its leadership with the long-term goals of the organization. The move also reflects a broader trend within the pharmaceutical industry, where companies are increasingly linking executive incentives to significant corporate events.

What's Next

The filing does not say what happens next, but the vesting schedule indicates that the upcoming merger with Indivior Pharmaceuticals will be a pivotal moment for both companies.